$599
Altimmune, Scholar Rock, Xeris, and Viatris Q2 ’24 Earnings
A series of cardiometabolic-related news items have been observed from Altimmune, Scholar Rock, Xeris Biopharma, and Viatris. Below, FENIX provides highlights and insights for the respective news items.